EP0946208A2 - Compositions a usages multiples et leurs procedes d'utilisation dans des systemes de desinfection et de nettoyage de lentilles de contact - Google Patents
Compositions a usages multiples et leurs procedes d'utilisation dans des systemes de desinfection et de nettoyage de lentilles de contactInfo
- Publication number
- EP0946208A2 EP0946208A2 EP97950687A EP97950687A EP0946208A2 EP 0946208 A2 EP0946208 A2 EP 0946208A2 EP 97950687 A EP97950687 A EP 97950687A EP 97950687 A EP97950687 A EP 97950687A EP 0946208 A2 EP0946208 A2 EP 0946208A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- enzyme
- composition
- bottle
- container
- housing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 221
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000004140 cleaning Methods 0.000 title claims abstract description 42
- 230000000249 desinfective effect Effects 0.000 title claims abstract description 24
- 102000004190 Enzymes Human genes 0.000 claims abstract description 181
- 108090000790 Enzymes Proteins 0.000 claims abstract description 181
- 239000004599 antimicrobial Substances 0.000 claims description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 18
- 108090000787 Subtilisin Proteins 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 239000004327 boric acid Substances 0.000 claims description 14
- 108010056079 Subtilisins Proteins 0.000 claims description 13
- 102000005158 Subtilisins Human genes 0.000 claims description 13
- 108090000631 Trypsin Proteins 0.000 claims description 13
- 102000004142 Trypsin Human genes 0.000 claims description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 13
- 239000012588 trypsin Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 11
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 101100162013 Arabidopsis thaliana MAPDA gene Proteins 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- 108700015005 N6-mAMP deaminase activity proteins Proteins 0.000 claims description 7
- 229920002362 Tetronic® 1304 Polymers 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 6
- 230000000712 assembly Effects 0.000 abstract description 2
- 238000000429 assembly Methods 0.000 abstract description 2
- 239000000645 desinfectant Substances 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 151
- 239000007788 liquid Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 22
- -1 polyethylene Polymers 0.000 description 16
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 238000007865 diluting Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 230000002797 proteolythic effect Effects 0.000 description 8
- 108010019160 Pancreatin Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 229940055695 pancreatin Drugs 0.000 description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 6
- 229940123208 Biguanide Drugs 0.000 description 6
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 150000004283 biguanides Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920002413 Polyhexanide Polymers 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229910021538 borax Chemical class 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003625 amylolytic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010061137 Ocular toxicity Diseases 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 108010059345 keratinase Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000327 ocular toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/086—Container, accessories or devices therefor
Definitions
- the present invention relates to the field of contact lens cleaning and disinfecting.
- this invention is directed to the provision of multi-purpose compositions and
- compositions methods for the preparation of these compositions.
- the invention is also directed to methods
- Patent No. 3,910,296 (Karageozian, et al.).
- chemical agents include organic anti ⁇
- microbials such as benzalkonium chloride and chlorhexidine
- inorganic anti-microbials such as benzalkonium chloride and chlorhexidine
- proteolytic enzymes and polymeric biguanides or polymeric quaternary ammonium compounds are included in the specification.
- compositions has been necessary to ensure stability of the enzymes prior to use.
- liquid enzyme compositions are inherently unstable. When a proteolytic enzyme is placed in
- the enzyme may lose
- stabilizing agents can protect enzymes from chemical instability
- the lens is to be simultaneously cleaned and disinfected. Furthermore, since the amount of
- liquid enzyme composition placed in a diluting composition is controlled by the user, user error
- Patent Applications Nos. 92-370197; 92-143718; and 92-243215 describe liquid enzyme
- compositions for treating contact lenses are provided.
- Soft contact lenses become soiled by collecting various debris and also
- compositions wherein the enzyme is in a dilute concentration, and the compositions, therefore,
- FIG. 1 is a perspective view of a preferred embodiment of the invention.
- FIG. 2 is a elevation view of a preferred embodiment of the invention.
- FIG. 3 is an exploded elevation view of a preferred embodiment of the invention.
- FIG. 4 is an exploded cross-section view of a preferred embodiment of the invention
- FIG. 5 is a cross-section view about line 5-5 of FIG 2 of a preferred embodiment of the invention.
- FIG. 6 is a cross-section view about line 5-5 of FIG. 2 of a preferred embodiment of the
- FIG. 7 is a top plan view of a housing of the invention.
- FIG. 8 is a bottom plan view of a cap and collar of the invention.
- the present invention is directed to two-part systems which provide for the generation
- the present invention is also directed to methods of simultaneously cleaning and
- the two-part system comprises an
- enzyme cleaning composition an aqueous composition and one or more anti-microbial
- the enzyme composition provides a concentrated amount of an enzyme.
- aqueous composition provides a diluting solution.
- the anti-microbial agent is contained in
- the two-part system uses a two-compartment device capable of keeping separate an
- Still another advantage of this feature is that it eliminates
- Another feature of the present invention is that the enzyme component is kept separate
- the two components are combined and mixed aseptically, forming the multi-purpose
- the multi-purpose composition can then be used for a period of from about 1-3
- the cleaning and disinfecting compositions of the present invention may utilize
- compositions and methods of the present invention provide greater than
- the present invention is directed to the use of a sterile two-part system for the
- the present invention is also directed to methods of cleaning and disinfecting contact lenses by
- Part I is a sterile enzyme
- Part II containing solid (powder or tablet) or liquid composition and the second part (“Part II") is a
- sterile diluting composition An anti-microbial agent is further required, and may be included
- the present invention requires the use of a two-compartment device to store and mix
- Figure 1 illustrates a preferred two-part bottle assembly for use with the two-part/multi-
- compositions of the present invention are purpose compositions of the present invention.
- assembly 1 generally comprises bottle 2 and container 4.
- bottle 2 comprises neck 13, opening 10, external rings 12
- Bottle 2 is made generally of molded polyethylene, although other materials such as
- PET polyethyleneterphlalate
- P/P polypropylene
- container 4 comprises housing 5, plunger 6, cap 8 and
- Housing 5 comprises hollow cylinder 14 and cap 16. Cylinder 14 has external
- Stops 23 are disposed annularly about exterior 38 of cylinder 14 (FIG. 7).
- Cap 16 has thin cross-sectional thickness 49 about its circumference.
- Cap 16 has protruding internal
- cap 16 is coaxially disposed within cap 16 such that top end 15 and bottom
- Plunger 6 comprises hollow cylinder 24, open end 22, dispensing
- Open end 22 has tooth 39 and is thinner in cross-sectional thickness than
- collar 28 has tab 29, spokes 19 and perforation 27 which forms ends 31.
- components are generally made of molded high density polyethylene or polycarbonate, but
- ABS butadiene styrene
- container 4 is put together by first adding enzyme cleaning
- composition 7 to hollow cylinder 14 of housing 5, ringing collar 28 over cylinder 14, inserting
- spokes 19 of collar 28 are interspersed between both stops 21 of cap 8 and stops
- Aqueous composition 9 is added to bottle 2, container 4 is then placed over neck 13,
- cap 16 is forced down on neck 13 such that rings 20 compress radially against neck 13, and
- exterior rings 12 compress against interior 47 of cap 16, forming an air-tight seal.
- collar 28 is first removed from container 4 by screwing cap 8 downward
- plunger 6 is simultaneously pushed downward causing
- plunger 6 to descend cylinder 14.
- membrane 18 of housing 5 sharp
- composition contained in housing 5 is exposed to interior 1 1 of bottle 2 and falls into aqueous
- Bottle 2 may then be inverted and shook, thus affecting the
- composition may now be dispensed through this channel to an appropriate container for
- a blister pouch and piercing means may be utilized as the
- the present invention is comprised of two separate compositions which
- Part I comprises an enzyme and Part II comprises an enzyme
- the resultant multi-purpose composition may contain various other ingredients.
- agents but must contain: 1) an anti-microbial agent, 2) an enzyme, 3) a buffering agent, 4) a
- compositions of the present invention are
- multi-purpose compositions will be physiologically compatible with the eye.
- the Part I sterile enzyme composition of the present invention is generally composed of
- the enzyme composition may be formulated as a
- Dry powder or tablet compositions may be preferred when the Part I
- powder composition will include bulking agents to carry the relatively small volume of enzyme
- Such bulking agents typically include polyols (e.g., mannitol or
- soribitol polyethylene glycols (molecular weights greater than 1000) and sugars.
- excipients may include salts such as NaCl, chelating agents such as EDTA, and buffering
- agents such as Tris.
- Other additives may include surfactants to ease dispersion and dissolution
- Preferred enzyme powder compositions comprise mannitol and
- PEG-5000 polyethylene glycol-5000
- Enzyme tablet compositions and methods of manufacturing are known in the art.
- Enzyme tablets require the use of bulking agents and binding agents. Additionally, tablets may
- effervescing agents such as bicarbonate to expedite dissolution of the tablet into the
- Liquid enzyme compositions are preferred Part I compositions of the present invention.
- Enzymes contained in Part I liquid compositions may be solubilized in aqueous
- compositions or dispersed in non-aqueous compositions are compositions or dispersed in non-aqueous compositions.
- Aqueous enzyme compositions are generally preferred due to their ease of preparation
- Aqueous enzyme compositions typically comprise one or more polyol(s) and
- a borate or boric acid compound a borate or boric acid compound.
- inventions comprise a 2-3 carbon polyol and a borate or boric acid compound.
- a 2-3 carbon polyol and a borate or boric acid compound.
- 2-3 carbon polyol refers to a compound with 2 to 3 carbon atoms and at least two
- Examples of 2-3 carbon polyols are glycerol, 1,2-propane diol ("propylene
- glycol 1,3-propane diol and ethylene glycol.
- Glycerol is the most preferred 2-3 carbon
- compositions of the present invention include alkali metal salts of borate, boric acid and borax.
- excipients which may be included in the Part I aqueous enzyme compositions include
- divalent ions such as calcium
- enzyme stabilizing organic acids such as benzoic acid and
- surfactants such as alkylethoxylates.
- inventions generally comprise a crystalline enzyme uniformly dispersed in a water-soluble
- organic liquid examples include polyoxyethylenes (e.g., PEG-400) and alkoxy
- polyoxyethylenes such as methoxy polyethylene glycols.
- the enzyme is in this composition, in this composition, in
- the anti-microbial agent(s) of the present invention may be included in any suitable pharmaceutically acceptable medium.
- the anti-microbial agent(s) of the present invention may be included in any suitable pharmaceutically acceptable medium.
- Part I enzyme composition are aseptically processed generally by
- inventions include all enzymes which: (1) are useful in removing deposits from contact lenses;
- proteolytic enzymes used herein must have at least a partial capability to hydrolyze
- amylolytic or related activities associated with the proteolytic activity may be neutral,
- the present invention include, but are not limited to: pancreatin, trypsin, subtilisin, collagenase, keratinase, carboxypeptidase, bromelain, aminopeptidase, elastase, Aspergillo peptidase,
- pronase E from S griseus
- dispase from Bacillus polymyxa
- Microbially derived enzymes such as those derived from Bacillus. Streptomyces. and
- Aspergillus microorganisms represent a preferred type of enzyme which may be utilized in the
- subtilisin neutral or slightly alkaline proteases generically called "subtilisin” enzymes.
- enzymes including those enzymes having proteolytic and mixed
- proteolytic/lipolytic/amylolytic activity The enzymes contemplated by this invention can be any enzymes contemplated by this invention.
- the enzymes contemplated by this invention can be any enzymes contemplated by this invention.
- Preferred genetically modified enzymes include BPN' subtilisin variants, such as those
- subtilisins and variants include subtilisin Carlsberg, subtilisin PB92, subtilisin 309, subtilisin
- subtilisin 168 subtilisin DY and truncations, modifications and variants thereof.
- modifications include “pegylation,” i.e., covalent bonding of polyoxyethylene
- glycol derivatives to the enzymes as well as monomeric covalent additions to the enzymes
- compositions of the present invention It is believed that alkylation of hydro lyrically sensitive compounds.
- Subtilisin and trypsin are preferred enzymes, and genetically modified subtilisin BPN's
- Subtilisin is derived from
- Bacillus bacteria and is commercially available from various commercial sources including
- Subtilisin BPN' variants as described above are genetically modified subtilisins which have
- Pancreatin is extracted from mammalian pancreas, and is commercially available from
- Pancreatin USP is a mixture of
- pancreatin 9X The most preferred form of pancreatin is Pancreatin 9X. As utilized herein, the term
- Pantcreatin 9X means a filtered (0.2 microns) pancreatin containing nine times the USP
- the Part I enzyme concentration will depend on various factors, such as: the enzyme or
- invention may be prepared with initial amounts of enzyme that exceed the amount necessary to
- Part I enzyme compositions of the present invention will preferably contain one or more
- enzymes in an amount of from about 100-100,000 PAU/g or 100-100,000 PAU/mL.
- Part I enzyme compositions will contain an effective amount of one or
- composition of the present invention is referred to as "an amount effective to clean the
- concentration in the multi-purpose composition of from about 1-100 PAU/mL of solution
- proteolytic activity unit or "PAU” is defined as the amount of enzyme activity necessary to generate one microgram (meg) of tyrosine per minute (“meg Tyr/min”), as determined by the
- casein substrate (0.65% casein w/v) is equilibrated for 10 minutes
- composition by solubilizing and diluting the Part I composition in PBS buffer.
- the sample concentration is then determined by comparison to a tyrosine standard curve.
- Part I concentration is then calculated by taking into account the dilution ratio.
- the Part II aqueous compositions provide the volume of distilled water necessary for
- the multi-purpose compositions of the present invention In general, the Part II composition
- Part I compositions may be ophthalmically compatible solution.
- Part I compositions may be ophthalmically compatible solution.
- Part II compositions may provide only a percentage of these ingredients, or none at all.
- Part II compositions utilized in the present invention may contain various other ingredients
- components such as suitable buffering agents, chelating and/or sequestering agents and tonicity
- the Part II compositions may also contain surfactants. As stated above, the
- the Part II compositions may also be included in the Part II compositions.
- the Part II may also be included in the Part II compositions.
- the Part II may also be included in the Part II compositions.
- the Part II may also be included in the Part II compositions.
- compositions will contain one or more anti-microbial agents (e.g., PHMB or polyquaternium-
- anti-microbial agents e.g., PHMB or polyquaternium-
- a buffer e.g., borate
- citrates e.g., citrates
- tonicity agents e.g., NaCl, sugars
- a chelating agent e.g., sodium citrate
- EDTA EDTA
- surfactants e.g., block copolymers
- compositions such as amino alcohols and alkylamines, may also be used.
- Preferred Part II compositions comprise polyquaternium-1, sodium borate, boric acid,
- MAPDA MAPDA
- lenses including rigid gas-permeable (“RGP”) lenses and soft lenses.
- RGP rigid gas-permeable
- the multi-purpose compositions may be optimized to effect maximum
- contact lenses are electronegatively charged, they tend to bind enzymes with high isoelectric
- the cleaning obtained with the liquid enzyme compositions of the present invention is a
- the soaking times utilized will generally vary from about 1 hour to
- the cleaning methods of the present invention involve the use of a small amount of the
- the present invention may vary, depending on the enzyme concentration, as described above, as
- the nature of the lens care regimen e.g., the frequency
- cleaning agents e.g., surfactants.
- surfactants e.g., surfactants
- Part I composition of a Part I compostion will be added to about 120 mL of a Part II composition, although greater
- anti-microbial activity of anti-microbial agents The anti-microbial activity of disinfecting
- polymeric quaternary ammonium compounds such as polyquaternium-1
- polymeric quaternary ammonium compounds and particularly those of Formula
- the multi-purpose compositions of the present invention will have tonicities/osmolalities in the range of hypotonic to isotonic, and more
- mOs/kg milliOsmoles per kilogram
- 300 mOs/kg is particularly preferred, and an osmolality of about 220 mOs/kg is most preferred.
- the cleaning and disinfecting methods of the present invention utilize a multi-purpose
- composition of the present invention containing an anti-microbial agent.
- Anti-microbial agents include anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial agents, anti-microbial
- polymeric anti-microbial agent refers to any organic compound
- polymeric anti-microbial agents include: polyquaternium-1, which is a polymeric quaternary
- PAPB polymeric biguanide
- suitable in the methods of the present invention include: other quaternary ammonium
- anti-microbial agents used herein are preferably employed in the absence of mercury-
- the most preferred anti-microbial agents are polymeric quaternary ammonium
- R] and R 2 can be the same or different and are selected from:
- polyquaternium-1 which is also known as
- Polyquaternium-1 is a mixture of the above
- anti-microbial agents are utilized in the methods of the present
- agent employed will vary, depending on factors such as the type of lens care regimen in which
- the method is being utilized.
- the use of an efficacious daily cleaner in the lens is being utilized.
- the use of an efficacious daily cleaner in the lens is being utilized.
- care regimen may substantially reduce the amount of material deposited on the lenses
- microorganisms including microorganisms, and thereby lessen the amount of anti-microbial agent required to
- the type of lens being treated e.g., "hard” versus “soft” lenses
- the type of lens being treated may also be used.
- (I) is about 0.001% by weight.
- the methods of the present invention will typically involve adding about 2-10 mL of a
- the contact lenses are first rubbed with a multi ⁇
- the lens will typically be soaked overnight, but shorter or longer
- composition of the present invention are described below:
- liquid enzyme composition represents a preferred enzyme composition
- Calcium chloride and boric acid are dispersed in 30% of the volume of purified water.
- PEG and glycerol are then added.
- the pH of the solution is adjusted, and the enzyme is then added.
- composition is the sterile filtered using a 0.2 ⁇ m filter.
- the ingredients are dissolved with 90% of the volume of purified water, the pH is
- composition is then sterile
- Preferred amounts include 1 mL of
- the enzyme composition and 120 mL of the aqueous composition.
- liquid enzyme composition of the present invention The following is an example of a liquid enzyme composition of the present invention:
- the above formulation is prepared by first sequentially mixing propylene glycol,
- the enzyme composition is then sterile filtered (0.2 ⁇ m filter).
- optimal pH of the above formulation will be in the range of 5-7; a pH of 6 is most preferred.
- the tablets are generally prepared by first mixing the appropriate amounts of each of
- the tablets may then be sterilized by the method of
- the enzyme and lactose are dissolved in water (lg of enzyme/lactose per 1 mL of water) and sterile filtered using a 0.2 ⁇ m filter. The sterile enzyme solution as then aseptically lyophilized.
- Part II compositions are prepared in a similar way as those of Example 1, above.
- the Part I and II compositions described in the Examples above will be combined, stored and mixed in a single bottle assembly in various quantities. In general, preferred amounts will be:
- Part i 1 g of powder or 1 tablet of a solid enzyme composition, or 1 ml of liquid enzyme composition. Part II: about 120 ml
- the preferred enzyme activity in the final multi-purpose solution will be about 5-25 PAU/ml.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Detergent Compositions (AREA)
- Eyeglasses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3283996P | 1996-12-13 | 1996-12-13 | |
| US32839P | 1996-12-13 | ||
| PCT/US1997/021579 WO1998025650A2 (fr) | 1996-12-13 | 1997-11-24 | Compositions a usages multiples et leurs procedes d'utilisation dans des systemes de desinfection et de nettoyage de lentilles de contact |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0946208A2 true EP0946208A2 (fr) | 1999-10-06 |
Family
ID=21867099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97950687A Ceased EP0946208A2 (fr) | 1996-12-13 | 1997-11-24 | Compositions a usages multiples et leurs procedes d'utilisation dans des systemes de desinfection et de nettoyage de lentilles de contact |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0946208A2 (fr) |
| JP (1) | JP2001508675A (fr) |
| KR (1) | KR20000057525A (fr) |
| CN (1) | CN1251533A (fr) |
| AU (1) | AU721951B2 (fr) |
| CA (1) | CA2274753A1 (fr) |
| NZ (1) | NZ336203A (fr) |
| WO (1) | WO1998025650A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358897B1 (en) * | 1996-06-07 | 2002-03-19 | Alcon Laboratories, Inc. | Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems |
| US6228323B1 (en) | 1996-12-13 | 2001-05-08 | Alcon Laboratories, Inc. | Multi-purpose compositions containing an alkyl-trypsin and methods of use in contact lens cleaning and disinfecting |
| US6814088B2 (en) | 1999-09-27 | 2004-11-09 | The Procter & Gamble Company | Aqueous compositions for treating a surface |
| US6716805B1 (en) | 1999-09-27 | 2004-04-06 | The Procter & Gamble Company | Hard surface cleaning compositions, premoistened wipes, methods of use, and articles comprising said compositions or wipes and instructions for use resulting in easier cleaning and maintenance, improved surface appearance and/or hygiene under stress conditions such as no-rinse |
| JP4286480B2 (ja) * | 2001-09-17 | 2009-07-01 | 株式会社メニコン | 殺菌液 |
| TWI322828B (en) * | 2002-12-23 | 2010-04-01 | Alcon Inc | Use of multifunctional surface active agents to clean contact lenses |
| US20050119141A1 (en) * | 2003-12-01 | 2005-06-02 | Irene Quenville | Stability enhancement of solutions containing antimicrobial agents |
| US20070264226A1 (en) * | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8812109D0 (en) * | 1988-05-23 | 1988-06-29 | Ifejika C | Method for daily cleaning & protein deposit removal for contact lenses |
| CA2009118C (fr) * | 1989-02-21 | 1996-02-27 | Mary F. Mowrey-Mckee | Methode et compose pour nettoyer et desinfecter les verres de contact |
| CA2041871C (fr) * | 1990-05-09 | 2000-07-11 | Ruth A. Rosenthal | Nettoyage et desinfection des lentilles corneennes a l'aide d'une association d'enzymes et de composes polymeriques d'ammonium quaternaire |
| US5356555A (en) * | 1992-09-14 | 1994-10-18 | Allergan, Inc. | Non-oxidative method and composition for simultaneously cleaning and disinfecting contact lenses using a protease with a disinfectant |
| US5723421A (en) * | 1995-06-07 | 1998-03-03 | Alcon Laboratories, Inc. | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems |
| US5605661A (en) * | 1995-08-18 | 1997-02-25 | Alcon Laboratories, Inc. | Methods of using liquid enzyme compositions containing mixed polyols |
| US5718895A (en) * | 1995-11-16 | 1998-02-17 | Alcon Laboratories, Inc. | Enzymes with low isoelectric points for use in contact lens cleaning |
-
1997
- 1997-11-24 JP JP52671798A patent/JP2001508675A/ja active Pending
- 1997-11-24 EP EP97950687A patent/EP0946208A2/fr not_active Ceased
- 1997-11-24 NZ NZ336203A patent/NZ336203A/xx unknown
- 1997-11-24 WO PCT/US1997/021579 patent/WO1998025650A2/fr not_active Application Discontinuation
- 1997-11-24 CA CA002274753A patent/CA2274753A1/fr not_active Abandoned
- 1997-11-24 CN CN97181279A patent/CN1251533A/zh active Pending
- 1997-11-24 AU AU53624/98A patent/AU721951B2/en not_active Ceased
- 1997-11-24 KR KR1019990705232A patent/KR20000057525A/ko not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9825650A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1251533A (zh) | 2000-04-26 |
| AU721951B2 (en) | 2000-07-20 |
| NZ336203A (en) | 2000-01-28 |
| CA2274753A1 (fr) | 1998-06-18 |
| WO1998025650A2 (fr) | 1998-06-18 |
| WO1998025650A3 (fr) | 1998-11-12 |
| KR20000057525A (ko) | 2000-09-25 |
| AU5362498A (en) | 1998-07-03 |
| JP2001508675A (ja) | 2001-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6228323B1 (en) | Multi-purpose compositions containing an alkyl-trypsin and methods of use in contact lens cleaning and disinfecting | |
| US5948738A (en) | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| US5718895A (en) | Enzymes with low isoelectric points for use in contact lens cleaning | |
| EP0456467A2 (fr) | Nettoyage et désinfection de lentilles de contact par des combinaisons de composés polymériques d'ammonium quaternaire et d'enzymes | |
| US6139646A (en) | Alkyl trypsin compositions and methods of use in contact lens cleaning and disinfecting systems | |
| US5605661A (en) | Methods of using liquid enzyme compositions containing mixed polyols | |
| AU706542B2 (en) | Stable liquid enzyme compositions and methods of use | |
| US5604190A (en) | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| AU721951B2 (en) | Multi-purpose compositions and methods of use in contact lens cleaning and disinfecting systems | |
| US6214596B1 (en) | Liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| US6184189B1 (en) | Liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| CA2274340A1 (fr) | Compositions et methodes a usages multiples pour le nettoyage de verres de contact et des systemes desinfectants | |
| MXPA99005568A (en) | Multi-purpose compositions and methods of use in contact lens cleaning and disinfecting systems | |
| WO2000012663A1 (fr) | Compositions a enzyme liquide pour le nettoyage et la desinfection des verres de contact | |
| HK1026153A (en) | Multi-purpose compositions and methods of use in contact lens cleaning and disinfecting systems | |
| WO1998022567A1 (fr) | Compositions d'enzymes liquides stables pour le nettoyage de lentilles de contact | |
| HK1020986A (en) | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| HK1014029B (en) | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems | |
| MXPA97009642A (en) | Stable liquid enzyme compositions and methods of |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990603 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20000728 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| RTI1 | Title (correction) |
Free format text: BOTTLE ASSEMBLY AND METHOD FOR TREATING A CONTACT LENS |
|
| RTI1 | Title (correction) |
Free format text: BOTTLE ASSEMBLY AND METHOD FOR TREATING A CONTACT LENS |
|
| RTI1 | Title (correction) |
Free format text: BOTTLE ASSEMBLY AND METHOD FOR TREATING A CONTACT LENS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20020916 |